Compare TJX Companies Inc (TJX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? TJX Companies Inc trades at $153.94 (market cap $172.05B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $134.25B). The key difference: TJX Companies Inc is the larger of the two by market cap, and TJX Companies Inc pays a 1.23% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TJX | VRTX | |
|---|---|---|
Market Cap | $172.05B | $134.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $168.41 | $529.65 |
52-Week Low | $132.62 | $376.62 |
Enterprise Value | $180.65B | $128.37B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX trades at $158.80, down 1.59% on the day, but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $158 and resistance at $160, while analyst consensus remains overwhelmingly positive with 88% buy ratings and a $181.80 price target. Recent financial performance demonstrates solid revenue growth from $48.5B in 2022 to $56.4B in 2025, with net income margins expanding to 8.63%.
TJX presents a compelling investment case with strong operational execution and market share gains in discount retail. The primary upside catalyst is continued earnings outperformance and expansion into new markets, while risks include consumer spending sensitivity and competitive pressures. With projected 2026 revenue of $61.6B and net income of $5.8B, the company's growth trajectory supports the bullish analyst sentiment despite premium valuation multiples.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
